Therapeutic Potential of Platelet-Rich Plasma in the Intestinal Phase of Trichinella spiralis Infection: An experimental Study

Bibliographic Information
Authors: Zalat R.S.; Atta S.A.; El-Wakil E.S.
Journal: Egyptian Journal of Medical Microbiology (Egypt)
Publisher: Egyptian Society for Medical Microbiology (ESMM)
Publication Date: 1 April 2026
Volume / Issue: Volume 35 / Issue 2
Pages: 11–17
ISSN: 11102179
DOI: 10.21608/ejmm.2025.407793.1801
Scopus: View on Scopus
Document Type: Article
Authors and Affiliations
Zalat R.S., Department of Parasitology, Theodor Bilharz Research Institute, Kornaish El Nile, Warrak El-Hadar, Imbaba (P.O. 30), Giza, 12411, Egypt; Atta S.A., Department of Immunology, Theodor Bilharz Research Institute, Kornaish El-Nile St, Giza, 12411, Egypt; El-Wakil E.S., Department of Parasitology, Theodor Bilharz Research Institute, Kornaish El Nile, Warrak El-Hadar, Imbaba (P.O. 30), Giza, 12411, Egypt
Abstract
Background: Trichinellosis, a zoonotic disease with significant clinical ramifications, has been classified as an emerging re-emerging illness. Albendazole (ALB), the drug used to treat trichinellosis, has been connected to several adverse reactions. Researchers are thus motivated to seek out new alternative therapeutics. Platelet-rich plasma (PRP) has the advantage of being an autologous product with no known adverse effects, making it a viable option for biological therapies in various healthcare settings, including parasitic infection. Objective: This study aimed to look into PRP's therapeutic effects against the intestinal phase of murine trichinosis. Methodology: 30 Laboratory-bred albino rats were randomly divided into five groups: normal model, infected model, ALB, PRP, and combination of ALB and PRP. The effectiveness of the treatment was evaluated by parasitological, histopathological, and immunological analysis. Results: All treated groups showed a statistically significant difference from the Con Post. group (GII). Combining the ALB and PRP displayed the highest reduction (93%) with the lowest adult T. spiralis worm mean count (6 ± 2.2). The ALB efficacy (83%) was higher than PRP (73%), and the difference was statistically significant (p < 0.001). The combination of ALB and PRP produced the most noticeable histopathological improvements in the small intestine and MPO and IL-6 markers in serum. Conclusion: This study's findings highlight PRP's substantial therapeutic potential during the intestinal stage of a T. spiralis infection, opening up new research on PRP as an adjuvant or alternative treatment for helminthic diseases. © 2026, Egyptian Society for Medical Microbiology (ESMM). All rights reserved.
Keywords
IL-6; intestinal phase; MPO; PRP; T. spiralis
Citation Information
Scopus Citations: 1
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
